Pluri Inc. (PLUR) stock
Close on Nov 11, 2026Market cap $14.81MP/E –Yield –
Pluri Inc. grew revenue 10.0% to $1.46M over the twelve months to Sep 30, 2026. Free cash flow was -$19.23M. At the latest close the market valued the company at $14.81M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $14.81M
- P/E ratio
- –
- Price to sales
- 10.15
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -129.78%
Fundamentals
- Revenue
- $1.46M
- Net income
- -$28.36M
- EPS, diluted
- -$2.44
- Free cash flow
- -$19.23M
- Book value per share
- -$1.84
- Diluted shares
- 12M
Trading
- Previous close
- $1.12
- Open
- $1.26
- Day's range
- $1.08 – $1.26
- Volume
- 30,569
- Average volume (20 days)
- 68,385
- Beta (5 years)
- 0.97
- 52-week range
- $0.85 – $4.87
- RSI (14 days)
- 54.5
- Volatility (1 year)
- 73.2%
- Relative volume
- 0.88×
- WACC
- 9.7%
Market cap history
Month-end market cap since 2009, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | PLUR | S&P 500 | Difference | PLUR per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +25.9% | -2.4% | +28.3 pts | ||
| 3 months | -31.4% | -1.2% | −30.3 pts | ||
| Year to date | -59.9% | +12.3% | −72.2 pts | ||
| 1 year | -71.0% | +12.4% | −83.5 pts | ||
| 3 years | -75.4% | +78.8% | −154.2 pts | -37.4% | +21.4% |
| 5 years | -94.8% | +75.2% | −170.0 pts | -44.7% | +11.9% |
| 10 years | -99.0% | +311.1% | −410.1 pts | -37.1% | +15.2% |
Fifteen years at a glance
Fiscal years 2012 to 2026 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Pluri filed with the SEC as exhibits to Form 8-K or 6-K
About Pluri
Biological Products, (No Diagnostic Substances)
Pluri Inc. is a biotechnology company that develops cell-based products, therapeutics, and related technologies using a proprietary three-dimensional cell expansion platform. The company's automated platform expands human, animal, and plant cells within a synthetic scaffold to support scalable cell manufacturing. Its activities encompass cell therapy and immunotherapy programs, contract development and manufacturing organization services, regenerative aesthetics and longevity initiatives, and food technology and bio-farming applications. Product candidates include placenta-derived cell therapies such as PLX-PAD and PLX-R18, as well as an allogeneic immunotherapy platform using placental mucosal-associated invariant T cells for solid tumors.
Company profile, executives and historyPluri stock: common questions
What is Pluri's stock price?
PLUR closed at $1.20 on Nov 11, 2026, up 7.14% on the day. Over the past 52 weeks it traded between $0.85 and $4.87.
What is Pluri's market cap?
Pluri was worth $14.81M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is PLUR's P/E ratio?
Pluri lost money over fiscal 2026 (diluted EPS -$2.44), so it has no meaningful P/E ratio.
How much revenue does Pluri make?
Pluri reported revenue of $1.46M for the twelve months to Sep 30, 2026, up 10.0% from a year earlier.
Does Pluri pay a dividend?
No. Pluri has not paid a cash dividend over the last twelve months.
How has PLUR stock performed over the past year?
Including dividends, PLUR returned -71.0% over the past year, against +12.4% for the S&P 500.
How many PLUR shares are sold short?
0M shares were sold short at the latest FINRA report, 1.37% of the float, or 1.0 days of average trading volume.
Who are Pluri's competitors?
Companies most similar to Pluri by business, industry and size include SCNI, PROK, SABS, LGVN, DYAI.
See a number that looks wrong?